Terbium Radionuclides for Theranostics Applications: A Focus On MEDICIS-PROMED - Archive ouverte HAL
Article Dans Une Revue Physics Procedia Année : 2017

Terbium Radionuclides for Theranostics Applications: A Focus On MEDICIS-PROMED

Résumé

A new facility, named CERN-MEDICIS, is under construction at CERN to produce radionuclides for medical applications. In parallel, the MEDICIS-PROMED, a Marie Sklodowska-Curie innovative training network of the Horizon 2020 European Commission‘s program, is being coordinated by CERN to train young scientists on the production and use of innovative radionuclides and develop a network of experts within Europe. One program within MEDICIS-PROMED is to determine the feasibility of producing innovative radioisotopes for theranostics using a commercial middle-sized high-current cyclotron and the mass separation technology developed at CERN-MEDICIS. This will allow the production of high specific activity radioisotopes not achievable with the common post-processing by chemical separation. Radioisotopes of scandium, copper, arsenic and terbium have been identified. Preliminary studies of activation yield and irradiation parameters optimization for the production of Tb-149 will be described.

Dates et versions

hal-03903535 , version 1 (16-12-2022)

Identifiants

Citer

R. Formento Cavaier, F. Haddad, T. Sounalet, T. Stora, I. Zahi. Terbium Radionuclides for Theranostics Applications: A Focus On MEDICIS-PROMED. Physics Procedia, 2017, 90, pp.157-163. ⟨10.1016/j.phpro.2017.09.053⟩. ⟨hal-03903535⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

More